Curated News
By: NewsRamp Editorial Staff
August 23, 2024
Clene Announces Positive Results of Phase 2 ALS Trials for CNM-Au8
Discuss on Reddit
Discuss on SubstackTLDR
- Positive results of Phase 2 trials for CNM-Au8 could give Clene a competitive edge in developing a new ALS treatment.
- CNM-Au8 showed significant improvement in key biomarkers among ALS patients in Phase 2 trials, suggesting promise for new treatment.
- CNM-Au8's potential as a new ALS treatment offers hope for improving the lives of ALS patients in the near future.
- Clene's recent presentation at the Canaccord Genuity 44th Annual Growth Conference showcased promising updates and findings for CNM-Au8.
Impact - Why it Matters
This news matters as it highlights the potential of CNM-Au8 as a new treatment for ALS, providing hope for patients and their families. The positive results of the clinical trials and the company's pursuit of an accelerated approval pathway could lead to a significant impact on the treatment of ALS and the lives of those affected by the disease.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, announced positive results of two independently conducted Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8. Biomarker and efficacy data was submitted to the FDA for a granted Type C meeting request, with the company targeting an accelerated approval pathway. CEO Rob Etherington expressed optimism about CNM-Au8’s potential as a new ALS treatment and voiced hope that ALS patients will benefit sooner rather than later.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Announces Positive Results of Phase 2 ALS Trials for CNM-Au8
